Radiotheranostics Market Size, Share, Growth Report, Industry Trends and Future Outlook 2034
Global Radiotheranostics Market Growth, Size, Trends Analysis - By Radioisotope, By Approach, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: May-2025 | Report ID: HLCA25127 | Pages: 1 - 222 | Formats*: |
| Category : Healthcare | |||
According to SPER Market Research, the Global Radiotheranostics Market is estimated to reach USD 35.22 billion by 2034 with a CAGR of 13.74%.
Radiotheranostics Market Introduction and Overview
The report includes an in-depth analysis of the Global Radiotheranostics Market, including market size and trends, product mix, Applications, and supplier analysis. The market for radiotheranostics was estimated to be worth USD 9.72 billion in 2024 and is expected to rise at a compound annual growth rate (CAGR) of 13.74% from 2025 to 2034. The growing use of nuclear medicine in the treatment of a wide range of chronic conditions, as well as a growing need for precision medicine, are expected to boost the worldwide radiotheranostics market. Furthermore, an increased demand for radiotheranostics with biological activity to target specific disorders and evaluate therapy outcomes is boosting the global market. However, the short half-life of radioisotopes and high treatment costs are anticipated to limit market expansion.
By Radioisotope Insights
The Lutetium-177 sector is expected to grow at a profitable rate during the forecast period and held the greatest revenue share in 2024. The increasing availability and market acceptance of LU-177 products is what is propelling the expansion of the Lutetium-177 segment. Furthermore, Lu-177 has a longer half-life than other therapeutic isotopes, allowing for a longer course of treatment and possibly better patient outcomes.
By Approach Insights
It is anticipated that the targeted therapeutic sector will grow at the quickest CAGR over the forecast period. The strong pipeline of research and the growing importance of radiotheranostics in cancer treatment are the reasons for the segment's expansion. The recent commercialisation of therapeutic items, the expanding trend in nuclear medicine, and the increasing efforts of pharmaceutical businesses to fortify their supply chain are all contributing factors to the segment's rapid growth.
By Application Insights
In 2024, the oncology category held the largest market share and dominated the industry. The large availability of cancer radiotheranostics items in space is the reason for this high proportion. Additionally, recent product approvals, upcoming product releases, and the changing need for creating cutting-edge imaging tools and treatments solutions are all projected to propel industry expansion. Pluvicto, LUTATHERA, AZEDRA, and other cancer theranostics are a few examples. The effectiveness of cancer radiotheranostic drugs has increased due to the increased demand for nuclear medicine among medical professionals.
Regional Insights
North America had the largest revenue share in 2024 and is anticipated to keep this position in the future. The growth of the radiotheranostics market in North America is driven by efficient imaging technologies, precision medicine, and strong demand for therapeutic radiopharmaceuticals, along with many market players and their strategic initiatives.
Asia Pacific is expected to have a high CAGR over the projection period. The high frequency of cancer in the region, as well as increased investment in nuclear medicine, are important drivers of regional market growth.
Market Competitive Landscape
Key firms are implementing tactics including partnership, merger and acquisition, and new product development in an effort to grow their market share. Novartis AG, Bayer AG, Life Molecular Imaging, and others were market leaders in the global radiotheranostics market. These major companies have been creating a cutting-edge product line to satisfy demand worldwide. In order to remain competitive in the market, they have also been launching a number of innovations and diversifying their product lines.
Recent Developments:
- ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotechnology business established in Germany, stated in December 2023 that it has obtained an exclusive license to use radiolabeled folate derivatives in therapeutic and diagnostic applications for malignant tumours.
- In March 2023, Radiopharm Theranostics, an Australian radiopharmaceuticals producer, announced the acquisition of Pharma15 Corporation by its wholly-owned U.S. subsidiary. Pharma15 is a privately held venture established in the United States that is developing next-generation therapeutic radiopharmaceuticals for prostate cancer.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Radioisotope, By Approach, By Application |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited, ITM Radiopharma, Life Molecular Imaging, RadioMedix, IsoTherapeutics Group, LLC, Q BioMed Inc, Nordic Nanovector ASA. |
Key Topics Covered in the Report
- Global Radiotheranostics Market Size (FY’2021-FY’2034)
- Overview of Global Radiotheranostics Market
- Segmentation of Global Radiotheranostics Market By Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90)
- Segmentation of Global Radiotheranostics Market By Approach (Targeted Therapeutic, Targeted Diagnostic)
- Segmentation of Global Radiotheranostics Market By Application (Oncology, Non-oncology)
- Statistical Snap of Global Radiotheranostics Market
- Expansion Analysis of Global Radiotheranostics Market
- Problems and Obstacles in Global Radiotheranostics Market
- Competitive Landscape in the Global Radiotheranostics Market
- Details on Current Investment in Global Radiotheranostics Market
- Competitive Analysis of Global Radiotheranostics Market
- Prominent Players in the Global Radiotheranostics Market
- SWOT Analysis of Global Radiotheranostics Market
- Global Radiotheranostics Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER’s internal database
- 2.1.4. Premium insight from KOL’s
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTER’s Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Radiotheranostics Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Radiotheranostics Market
7. Global Radiotheranostics Market, By Radioisotope (USD Million) 2021-2034
- 7.1. Iodine-131
- 7.2. Iodine-123
- 7.3. Gallium-68
- 7.4. Lutetium-177
- 7.5. 18F with Y-90
- 7.6. Others
8. Global Radiotheranostics Market, By Approach (USD Million) 2021-2034
- 8.1. Targeted Therapeutic
- 8.2. Targeted Diagnostic
9. Global Radiotheranostics Market, By Application (USD Million) 2021-2034
- 9.1. Oncology
- 9.1.1. Thyroid Cancer
- 9.1.2. Neuroendocrine Tumor
- 9.1.3. Hepatocellular Carcinoma
- 9.1.4. Prostate Cancer
- 9.1.5. Others
- 9.2. Non-oncology
- 9.2.1. Neurological Disorders
- 9.2.2. Arthritis
- 9.2.3. Others
10. Global Radiotheranostics Market, (USD Million) 2021-2034
- 10.1. Global Radiotheranostics Market Size and Market Share
11. Global Radiotheranostics Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Novartis AG
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Bayer AG
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Progenics Pharmaceuticals, Inc.(Lantheus)
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Telix Pharmaceuticals Limited
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. ITM Radiopharma
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Life Molecular Imaging
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. RadioMedix
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. IsoTherapeutics Group, LLC
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Q BioMed Inc
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Nordic Nanovector ASA
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Radiotheranostics Market is projected to reach USD 35.22 billion by 2034, growing at a CAGR of of 13.74% during the forecast period.
Radiotheranostics Market grew in Market size from 2025. The Market is expected to reach USD 4.18 billion by 2034, at a CAGR of 13.74% during the forecast period.
Radiotheranostics Market CAGR of 13.74 % during the forecast period.
You can get the sample pages by clicking the link - Click Here
Radiotheranostics Market size is USD 35.22 billion from 2025 to 2034.
Radiotheranostics Market is covered By Technology, By Application
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited, ITM Radiopharma, Life Molecular Imaging, RadioMedix, IsoTherapeutics Group, LLC, Q BioMed Inc, Nordic Nanovector ASA.
The report includes an in-depth analysis of the Global Radiotheranostics Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
